Dreem Health, a leading virtual sleep clinic managed by Sunrise Group, has become the first sleep care service to join Amazon’s Health Benefits Connector. Amazon customers eligible for insurance-covered sleep services can discover and enroll in Dreem Health’s personalized care when browsing for healthcare services. More than 70 million Americans live with sleep […]
Tag: SLEEP DISORDERS
Clinical Trial of Early Morning Shift Workers Shows Promise of New Drug for Reducing Excessive Sleepiness
Many more people work very early morning shifts than overnight ones, and a large proportion struggle with excessive sleepiness from shift work disorder, leading to problems with focus, performance and safety. A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early […]
Lilly to Acquire Centessa to Advance Treatments for Sleep-Wake Disorders
Eli Lilly and Company and Centessa Pharmaceuticals plc, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to […]
Scrolling for Sleep: The Social Media Trends Impacting Americans’ Sleep Habits
Social media trends have become increasingly influential – even changing bedtime routines and sleep habits for many Americans. According to a 2025 survey from the American Academy of Sleep Medicine, 56% of U.S. adults have tried one of this year’s viral social media trends related to sleep. “Bed rotting,” which is […]
Sleep Medicine APPs Launch New Foundation to Bridge Education Gap and Build Community
The Sleep Medicine Advanced Practice Provider Foundation (SMAPP) announced its formation, establishing a first-of-its-kind non-profit dedicated to providing peer-led education and professional community for Advanced Practice Providers (APPs) working across the specialty of sleep medicine. The organization’s central mission is to empower nurse practitioners, physician assistants, and clinical pharmacologists with […]
Taking the Long View
Sleep medicine is undergoing a profound transformation. What was once centered around episodic, in-lab evaluations is evolving into a more continuous, personalized model of care. With the rapid rise of home sleep testing (HST) and increasingly sophisticated wearables, the integration of remote patient monitoring (RPM) into sleep medicine has moved […]
Specific Gut Bacteria Linked to Insomnia
Specific types of gut bacteria may increase or decrease the risk for insomnia, while insomnia itself may in turn alter the abundance of certain gut bacteria, a new study showed. However, outside experts challenged the investigators’ assertion that the link is causal. Investigators identified 14 groups of bacteria associated with increased […]
Sleep To Live Well Foundation Launches With Groundbreaking Sleep Wellness Report
The Sleep To Live Well Foundation issues an urgent warning in its groundbreaking 2025 State of Sleep Wellness Report, titled “THE SILENT EPIDEMIC: How Lack of Sleep Endangers Over Half of All Americans and Threatens Everyone.” The report unveils the Foundation’s initiatives to address this insufficient sleep crisis with Sleep Wellness—a holistic approach to […]
Streamline Your Patient Intake Process
A significant number of people in America are walking around with undiagnosed sleep disorders. Recent studies indicate 14.5 percent of adults in the U.S. have difficulty falling asleep, and 17.8 percent had difficulty staying asleep.1 While these alarming statistics highlight the urgent need for sleep disorder testing and treatment nationwide, […]
Avadel’s LUMRYZ Receives FDA Orphan Drug Designation for Idiopathic Hypersomnia
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may […]













